Related Experiment Videos
Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson's Disease
Verneri Ruonala1, Eero Pekkonen2, Olavi Airaksinen3
1Department of Applied Physics, University of Eastern Finland, Kuopio, Finland.
Frontiers in Neurology
|February 21, 2018
Summary
Objective wireless measurements can assess Parkinson's disease (PD) motor symptoms during levodopa challenge tests. This technology offers a feasible way to evaluate treatment effectiveness and patient eligibility for deep-brain stimulation (DBS).
Area of Science:
- Biomedical Engineering
- Neuroscience
- Movement Disorders
Background:
- Levodopa is the primary treatment for Parkinson's disease (PD) motor symptoms, including rigidity, tremor, and bradykinesia.
- Objective and feasible measurements are needed to assess PD motor symptoms during levodopa challenge tests, crucial for deep-brain stimulation (DBS) eligibility.
- Current assessment methods rely on subjective scales like the UPDRS-III, highlighting a need for more objective quantification.
Purpose of the Study:
- To evaluate the feasibility and effectiveness of wireless wearable sensors for objectively measuring Parkinson's disease motor symptoms.
- To analyze electromyographic (EMG) and kinematic signals during a levodopa challenge test in advanced PD patients.
- To determine if principal component and spectral analyses of sensor data can reflect levodopa's impact on motor symptoms.
Main Methods:
- Twelve advanced PD patients undergoing DBS evaluation participated.
- Wireless EMG and kinematic sensors recorded muscle activity and arm movements during isometric tension and passive flexion-extension tasks.
- Data were analyzed using parametric, principal component, and spectral approaches before and after levodopa administration.
Main Results:
- Principal component analysis of isometric EMG signals showed significant reductions in PD-related characteristics post-levodopa.
- Spectral analysis of passive movement EMG signals revealed a significant decrease in involuntary muscle activity.
- These objective sensor-based findings were more pronounced during the levodopa challenge test than with personal medication.
Conclusions:
- Wireless wearable sensor technology provides objective and feasible measurements of motor symptoms in Parkinson's disease.
- This approach effectively quantifies the impact of levodopa medication during challenge tests, aiding in treatment assessment.
- The findings support the use of wearable sensors for evaluating PD motor function and guiding therapeutic decisions like DBS.